WAVE LIFE SCIENCES LTD. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- WAVE LIFE SCIENCES LTD. stock issued during period, value, new issues for the quarter ending 2025-06-30 was $11.10M, a 1929.07% increase year-over-year.
- WAVE LIFE SCIENCES LTD. stock issued during period, value, new issues for the quarter ending 2024-09-30 was $173.44M.
- WAVE LIFE SCIENCES LTD. stock issued during period, value, new issues for the quarter ending 2024-06-30 was $547.00K, a 67.90% decline year-over-year.
- WAVE LIFE SCIENCES LTD. stock issued during period, value, new issues for the quarter ending 2024-03-31 was $14.04M, a 59.45% decline year-over-year.
- WAVE LIFE SCIENCES LTD. stock issued during period, value, new issues for fiscal 2025 was $330.91M, a 53.34% increase from fiscal 2024.
- WAVE LIFE SCIENCES LTD. stock issued during period, value, new issues for fiscal 2024 was $215.80M, a 130.62% increase from fiscal 2023.
- WAVE LIFE SCIENCES LTD. stock issued during period, value, new issues for fiscal 2023 was $93.57M, a 82.69% increase from fiscal 2022.
- WAVE LIFE SCIENCES LTD. stock issued during period, value, new issues for fiscal 2022 was $51.22M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2025-12-31 | $330.91M 10-K · filed 2026-02-26 | |
| 2025-06-30 | $11.10M 10-Q · filed 2025-11-10 | |
| 2024-12-31 | $215.80M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $173.44M 10-Q · filed 2025-11-10 | |
| 2024-06-30 | $547.00K 10-Q · filed 2025-07-30 | |
| 2024-03-31 | $14.04M 10-Q · filed 2025-11-10 | |
| 2023-12-31 | $93.57M 10-K · filed 2026-02-26 | |
| 2023-06-30 | $1.70M 10-Q · filed 2023-11-09 | |
| 2023-03-31 | $34.62M 10-Q · filed 2023-11-09 | |
| 2022-12-31 | $51.22M 10-K · filed 2025-03-04 | |
| 2022-06-30 | $51.22M 10-Q · filed 2023-11-09 | |
| 2021-09-30 | $8.08M 10-Q · filed 2022-11-10 | |
| 2020-12-31 | $93.74M 10-K · filed 2022-03-03 | |
| 2020-09-30 | $93.74M 10-Q · filed 2021-11-10 | |
| 2019-12-31 | $161.79M 10-K · filed 2021-03-04 | |
| 2019-06-30 | $7.00K 10-Q · filed 2020-11-09 | |
| 2019-03-31 | $161.78M 10-Q · filed 2020-11-09 | |
| 2018-12-31 | $60.00M 10-K · filed 2020-03-02 | |
| 2018-06-30 | $60.00M 10-Q · filed 2019-11-05 | |
| 2017-12-31 | $93.51M 10-K · filed 2020-03-02 | |
| 2016-12-31 | $30.00M 10-K · filed 2019-03-01 | |
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $11.63M 10-K · filed 2018-03-12 |
| 2014-12-31 | $5.58M 10-K · filed 2017-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |